ImmunityBio
IBRX
95 hedge funds and large institutions have $70.4M invested in ImmunityBio in 2020 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 30 increasing their positions, 20 reducing their positions, and 16 closing their positions.
63% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 16
50% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 20
12% more funds holding
Funds holding: 85 → 95 (+10)
0.47% less ownership
Funds ownership: 9.9% → 9.43% (-0.47%)
44% less call options, than puts
Call options by funds: $2.68M | Put options by funds: $4.8M
45% less capital invested
Capital invested by funds: $129M → $70.4M (-$58.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$6.16M |
| 2 |
Two Sigma Advisers
New York
|
+$4.28M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.33M |
| 4 |
MOACM
Mutual of America Capital Management
New York
|
+$1.23M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$9.68M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$5.51M |
| 3 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$4.3M |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$2.27M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.11M |
IBRX Hedge Fund Activity: Q3 2020 in Review
95 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2020, worth a combined $70.4M — down 45% from $129M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new IBRX positions and 16 closed out — a net gain of 10 holders — while 30 added to existing stakes and 20 trimmed.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $6.16M. The largest seller was CVI Holdings, exiting entirely with an estimated $9.68M sold.
- 95 institutional investors held ImmunityBio (IBRX) as of Q3 2020, up from 85 in Q2 2020.
- Funds reported $70.4M of ImmunityBio stock for Q3 2020, down 45% quarter-over-quarter.
- 26 funds opened new ImmunityBio positions in Q3 2020 and 16 closed out, a net change of +10 holders.
- The largest ImmunityBio buyer in Q3 2020 was Two Sigma Investments, an estimated $6.16M added.
- The largest ImmunityBio seller in Q3 2020 was CVI Holdings, an estimated $9.68M sold.
Based on aggregated 13F filings for Q3 2020.